-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Sells $267,178.32 in Stock
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Sells $267,178.32 in Stock
Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Rating) insider Benjamin T. Dake sold 10,284 shares of Aerovate Therapeutics stock in a transaction that occurred on Friday, January 6th. The stock was sold at an average price of $25.98, for a total value of $267,178.32. Following the completion of the sale, the insider now directly owns 1,609 shares in the company, valued at approximately $41,801.82. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Benjamin T. Dake also recently made the following trade(s):
Get Aerovate Therapeutics alerts:- On Friday, November 11th, Benjamin T. Dake sold 6,198 shares of Aerovate Therapeutics stock. The stock was sold at an average price of $20.69, for a total value of $128,236.62.
- On Tuesday, November 8th, Benjamin T. Dake sold 8,373 shares of Aerovate Therapeutics stock. The shares were sold at an average price of $18.09, for a total value of $151,467.57.
- On Monday, October 17th, Benjamin T. Dake sold 4,185 shares of Aerovate Therapeutics stock. The shares were sold at an average price of $20.16, for a total value of $84,369.60.
- On Friday, October 14th, Benjamin T. Dake sold 110 shares of Aerovate Therapeutics stock. The shares were sold at an average price of $20.05, for a total value of $2,205.50.
Aerovate Therapeutics Stock Down 2.7 %
Shares of Aerovate Therapeutics stock opened at $25.30 on Thursday. The stock's fifty day moving average is $22.68 and its two-hundred day moving average is $20.16. The company has a market capitalization of $617.57 million, a PE ratio of -16.11 and a beta of 0.80. Aerovate Therapeutics, Inc. has a 52 week low of $7.74 and a 52 week high of $30.79.
Aerovate Therapeutics (NASDAQ:AVTE – Get Rating) last announced its quarterly earnings data on Monday, November 14th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.06). As a group, research analysts anticipate that Aerovate Therapeutics, Inc. will post -2.07 earnings per share for the current year.Institutional Investors Weigh In On Aerovate Therapeutics
Hedge funds have recently made changes to their positions in the company. Parkwood LLC purchased a new stake in shares of Aerovate Therapeutics in the 2nd quarter worth $32,000. Russell Investments Group Ltd. purchased a new stake in shares of Aerovate Therapeutics in the 2nd quarter worth $32,000. Chicago Partners Investment Group LLC purchased a new stake in shares of Aerovate Therapeutics in the 2nd quarter worth $226,000. Amalgamated Bank purchased a new stake in shares of Aerovate Therapeutics in the 1st quarter worth $27,000. Finally, Citadel Advisors LLC lifted its holdings in shares of Aerovate Therapeutics by 1.5% in the 3rd quarter. Citadel Advisors LLC now owns 1,615,578 shares of the company's stock worth $26,786,000 after buying an additional 23,569 shares during the period.
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on AVTE shares. BTIG Research raised Aerovate Therapeutics from a "neutral" rating to a "buy" rating and set a $27.00 target price on the stock in a research report on Tuesday, December 6th. Wedbush boosted their target price on Aerovate Therapeutics from $27.00 to $54.00 in a research report on Monday, December 12th.
Aerovate Therapeutics Company Profile
(Get Rating)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Featured Articles
- Get a free copy of the StockNews.com research report on Aerovate Therapeutics (AVTE)
- Bloom Energy Powers Up After an Upgrade, is it Worth the Risk?
- Why Hershey Is a Sweet Recession Stock
- Will Amazon Stock Be Delivering for Investors in 2023?
- The Analysts Shift Trucking Sentiment Back into Forward
- The Institutions Book A Flight With Boeing
Receive News & Ratings for Aerovate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerovate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Aerovate治疗公司(纳斯达克代码:AVTE-GET评级)内部人士本杰明·T·达克在1月6日(星期五)的一笔交易中出售了10,284股Aerovate治疗公司的股票。这只股票的平均售价为25.98美元,总价值为267,178.32美元。出售完成后,这位内部人士现在直接拥有该公司1,609股股票,价值约41,801.82美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可通过此超链接。
本杰明·T·达克最近还进行了以下交易:
到达充气治疗学警报:- 11月11日,星期五,本杰明·T·达克出售了6,198股Aerovate治疗公司的股票。这只股票的平均售价为20.69美元,总价值为128,236.62美元。
- 11月8日,星期二,本杰明·T·达克出售了8,373股Aerovate治疗公司的股票。这些股票的平均价格为18.09美元,总价值为151,467.57美元。
- 10月17日,星期一,本杰明·T·达克出售了4185股Aerovate治疗公司的股票。这些股票的平均价格为20.16美元,总价值为84,369.60美元。
- 10月14日,星期五,本杰明·T·达克出售了110股Aerovate治疗公司的股票。这些股票的平均价格为20.05美元,总价值为2205.50美元。
Aerovate治疗公司股价下跌2.7%
周四,Aerovate治疗公司的股票开盘报25.30美元。该股的50日移动均线切入位为22.68美元,200日移动均线切入位为20.16美元。该公司市值为6.1757亿美元,市盈率为-16.11,贝塔系数为0.80。Aerovate治疗公司的52周低点为7.74美元,52周高位为30.79美元。
Aerovate治疗公司(纳斯达克代码:AVTE-GET Rating)上一次公布季度收益数据是在11月14日(星期一)。该公司公布本季度每股收益(0.56美元),低于普遍预期的(0.50美元)和(0.06美元)。研究分析师预计,作为一个整体,Aerovate治疗公司本年度每股收益将达到2.07美元。机构投资者看好Aerovate治疗公司
对冲基金最近对他们在该公司的头寸进行了调整。Parkwood LLC在第二季度购买了Aerovate治疗公司价值3.2万美元的新股份。罗素投资集团有限公司在第二季度购买了价值3.2万美元的Aerovate治疗公司的新股份。芝加哥合作伙伴投资集团有限责任公司在第二季度购买了Aerovate治疗公司价值22.6万美元的新股份。合并银行在第一季度购买了Aerovate治疗公司价值2.7万美元的新股份。最后,Citadel Advisors LLC在第三季度增持了Aerovate治疗公司的股票1.5%。Citadel Advisors LLC现在拥有1,615,578股该公司股票,价值26,786,000美元,在此期间又购买了23,569股。
华尔街分析师预测经济增长
几位股票分析师最近纷纷加码中兴通讯的股票。BTIG Research在12月6日(星期二)的一份研究报告中将Aerovate治疗公司的评级从中性上调至“买入”,并为该股设定了27.00美元的目标价。韦德布什在12月12日星期一的一份研究报告中将Aerovate治疗公司的目标价格从27.00美元上调至54.00美元。
Aerovate治疗公司简介
(获取评级)
Aerovate治疗公司是一家临床阶段的生物制药公司,专注于开发能够改善美国罕见心肺疾病患者生活的药物。该公司专注于推进AV-101,这是一种治疗肺动脉高压的伊马替尼干粉吸入剂,目前处于2b期/3期试验。
专题文章
- 免费获取StockNews.com关于Aerovate治疗(AVTE)的研究报告
- Bloom Energy在升级后启动,值得冒这个险吗?
- 好时为什么是一只甜蜜的衰退股票
- 亚马逊股票是否会在2023年为投资者提供服务?
- 分析师将货运情绪转回远期
- 各机构预订波音航班
接受《Aerovate治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Aerovate治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧